OncoMatch/Clinical Trials/NCT06794775
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Is NCT06794775 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Nivolumab and Nivolumab + Ipilimumab for malignant melanoma stage iii.
Treatment: Nivolumab · Nivolumab + Ipilimumab — At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NEO study aims to compare these two regimens, where the PD-1/CTLA-4 combination is potentially more effective, but also associated with more side effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Melanoma
Disease stage
Required: Stage III
Performance status
WHO 0–1
Prior therapy
Cannot have received: checkpoint inhibitor
No prior immunotherapy targeting CTLA-4, PD-1 or PD-L1.
Cannot have received: BRAF inhibitor
No prior targeted therapy targeting BRAF and/or MEK.
Cannot have received: MEK inhibitor
No prior targeted therapy targeting BRAF and/or MEK.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06794775 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior checkpoint inhibitor, BRAF inhibitor, MEK inhibitor disqualifies patients from enrollment.
What disease stage is eligible?
Stage III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages